Combination Therapy for BRAF-V600E Metastatic CRCm

NCT06411600 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Encorafenib
DRUG: Cetuximab
DRUG: Bevacizumab

Sponsor

Vall d'Hebron Institute of Oncology